The levonorgestrel-releasing intrauterine system (LNG-IUS) is a conservative management option for atypical hyperplasia (AH) and low grade early stage endometrial cancer (EEC), but around 1 in 3 patients fail to respond to treatment. The aim of this study was to investigate if serum and/or tissue HE4 expression could predict response to LNG-IUS therapy. Patients with AH or presumed Stage I EEC had serum and endometrial samples taken at baseline and at 3-month intervals over 12 months post-insertion of LNG-IUS. 74 patients were recruited and baseline demographics recorded. Of 57 patients for whom response was histologically determinable, 39 (68%) were responders and 18 (32%) non-responders. Mean baseline serum HE4 was significantly lower in responders (62.1 ± 1.1 pM, 95% confidence interval (CI) 52.7-73.2), compared to non-responders (125.6 ± 1.3 pM, 95% CI 74.5-211.7, = 0.014), including when considering age, BMI, menopausal status, smoking status, and histological grade as covariables ( = 0.005). Baseline tissue HE4 expression was not significantly different in responders compared to non-responders ( = 0.999). Responders showed a significant mean reduction (-9.8 ± 3.4%, 95% CI -16.7 to -2.8%, = 0.008) in serum HE4 between baseline and 3 months ( = 0.008), whereas non-responders showed no significant change ( = 0.676). Neither responders nor non-responders showed a significant percentage change in serum HE4 from baseline beyond 3 months ( > 0.05). Change in serum HE4 between baseline and 3 and 6 months and tissue HE4 tissue expression between baseline and 3, 6, and 12 months was not significantly different in responders compared to non-responders ( > 0.05). This study suggests that baseline serum HE4, but not baseline tissue HE4 expression, is independently predictive of response to the LNG-IUS and could be used to guide management decisions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073190 | PMC |
| http://dx.doi.org/10.3390/cancers12020276 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of serum human epididymis protein 4 in children with chronic liver diseases.
Scand J Clin Lab Invest
December 2024
Clinical and Chemical Pathology Department, Faculty of Medicine, Benha University, Benha, Egypt.
The aim of this study was to evaluate the role of serum human epididymis protein 4 (HE4) as a non-invasive biomarker for the diagnosis of liver fibrosis in children with chronic liver diseases (CLD). This case-control study was conducted at Benha University Hospital, Egypt, involving 60 children with CLD and 60 healthy children as a control group. HE4 levels were measured by ELISA and compared with liver biopsy results.
View Article and Find Full Text PDFHuman epididymitis protein 4 as a biomarker of interstitial lung disease in patients with idiopathic inflammatory myopathies.
Clin Exp Rheumatol
December 2024
Department of Medicine-DIMED, Padova University Hospital, Padova, Italy.
Article Synopsis
- HE4 is a protein that helps promote fibrosis by preventing collagen breakdown; this study aimed to evaluate HE4 as a biomarker for interstitial lung disease (ILD) in patients with idiopathic inflammatory myopathies (IIMs).
- Researchers enrolled 90 IIMs patients and 42 healthy controls, finding that serum HE4 levels were significantly higher in patients with IIMs, particularly in those diagnosed with ILD.
- The study concluded that HE4 levels could serve as a useful biomarker for detecting and assessing ILD in IIMs patients, although there was no significant link between baseline HE4 and progressive fibrosing ILD in follow-up cases.
The NF-κB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancer.
PLoS One
December 2024
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, United States of America.
Ovarian cancer is the leading cause of death among gynecologic malignancies. Despite recent advancements in targeted therapies such as PARP inhibitors, recurrence is common and frequently resistant to existing therapies. A powerful diagnostic tool, coupled with a comprehensive understanding of its implications, is crucial.
View Article and Find Full Text PDFClinical Utility and Diagnostic Accuracy of ROMA, RMI, ADNEX, HE4, and CA125 in the Prediction of Malignancy in Adnexal Masses.
Cancers (Basel)
November 2024
Unit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35122 Padua, Italy.
Objective: We aimed to compare the clinical utility and diagnostic accuracy of the ADNEX model, ROMA score, RMI I, and RMI IV, as well as two serum markers (CA125 and HE4) in preoperative discrimination between benign and malignant adnexal masses (AMs).
Methods: We conducted a retrospective study extracting all consecutive patients with AMs seen at our Institution between January 2015 and December 2020. Accuracy metrics included sensitivity (SE), specificity (SP), and area under the receiver operating characteristic curve (AUC), and their 95% confidence intervals (CI) were calculated for basic discrimination between AMs.
Predictive Role of HE4 in Diagnosis of Ovarian Tumors.
J Obstet Gynaecol India
October 2024
Obstretrics and Gynecology, IGIMS, Patna, India.
Background: Approximately 20% of women develop an ovarian cyst or pelvic mass at some point in their lives. Due to high false positivity of CA-125, women with various benign ovarian tumors simulating malignant masses undergo extensive debulking surgery resulting in increased morbidity. Serum HE4 is a useful test for better discrimination of benign or malignant nature of pelvic masses in preoperative period.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!